
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
France will build a new aircraft carrier as it increases defense spending - 2
A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats - 3
Find the Abilities Required for Advanced Advertising Position - 4
All that You Really want to Be aware of Dental Inserts Facilities - 5
The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
Vote In favor of Your Number one Game Control center
'I was diagnosed with incurable brain cancer on holiday'
The pace of hiring just fell to the lowest since 2011, outside of the pandemic
4 Sound blocking Earphones for Prevalent Sound and Solace
Instructions to Perform Fundamental Upkeep on Your Slam 1500.
Congo declares its latest Ebola outbreak over, after 43 deaths
Why this Tennessee special election has the 'whole world' watching
Latvia seeks emergency UN meeting over Russian missile attack on Lviv
Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.












